Treatment Guidelines - Issue 73 | The Medical Letter Inc.

Treatment Guidelines from The Medical Letter

FROM
ISSUE

September 1, 2008

View Complete Issue Table of Contents 2019

Issue 73

Drugs for Tobacco Dependence

Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.

Drugs for Tobacco Dependence

September 1, 2008 (Issue: 73)

Peptic ulcers caused by treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) are mainly gastric ulcers. The greater the number of office visits and the longer the counseling time, the higher the smoking cessation rates have been.

Show References Hide References

1. MC Fiore et al. Treating tobacco use and dependence: 2008 update. Clinical practice guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service; 2008.

2. LF Stead et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008: Jan 23; (1):CD000146.

3. P Hajek et al. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 1999; 159:2033.

4. JR Hughes et al. A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tobacco Control 2003; 12:21.

5. D Hatsukami et al. Effects of high dose transdermal nicotine replacement in cigarette smokers. Pharmacol Biochem Behav 2007; 86:132.

6. JE Rose et al. Precessation treatment with nicotine skin patch facilitates smoking cessation. Nicotine Tob Res 2006; 8:89.

7. S Shiffman and SG Ferguson. Nicotine patch therapy prior to quitting smoking: a meta-analysis. Addiction 2008; 103:557.

8. S Shiffman et al. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med 2002; 162:1267.

9. T Blöndal et al. Nicotine nasal spray with nicotine patch for smoking cessation: Randomised trial with six-year follow up. BMJ (Clinical research ed 1999; 318:285.

10. Drug Interactions. Med Lett Drugs Ther 2003; 45:46.

11. LA Kroon. Drug interactions with smoking. Am J Health Syst Pharm 2007; 64:1917.

12. JE Slemmer et al. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000; 295:321.

13. RD Hurt et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337:1195.

14. JS Ahluwalia et al. Sustained-release bupropion for smoking cessation in African Americans: Arandomized controlled trial. JAMA 2002; 288:468.

15. ML Muramoto et al. Randomized, double-blind, placebo-controlled trial of 2 dosages of sustained-release bupropion for adolescent smoking cessation. Arch Pediatr Adolesc Med 2007; 161:1068.

16. R Fossati et al. A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care. Arch Intern Med 2007; 167:1791.

17. GE Swan et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: A randomized trial. Arch Intern Med 2003; 163:2337.

18. DH Gonzales et al. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: A randomized placebocontrolled study. Clin Pharmacol Ther 2001; 69:438.

19. DE Jorenby et al. Acontrolled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340:685.

20. JT Hays et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation: a randomized, controlled trial. Ann Intern Med 2001; 135:423.

21. JT Hays et al. Bupropion for the treatment of tobacco dependence: Guidelines for balancing risks and benefits. CNS Drugs 2003; 17:71.

22. Varenicline (Chantix) for tobacco dependence. Med Lett Drugs Ther 2006; 48:66.

23. D Gonzales et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: Arandomized controlled trial. JAMA 2006; 296:47.

24. DE Jorenby et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA 2006; 296:56.

25. M Nides et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: Results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow- up. Arch Intern Med 2006; 166:1561.

26. HJ Aubin et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008; 63:717.

27. S Tonstad et al. Effect of maintenance therapy with varenicline on smoking cessation: Arandomized controlled trial. JAMA 2006; 296:64.

28. BF Grant et al. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psych 2004; 61:1107.

29. RD Goodwin et al. Nicotine dependence and mental disorders among adults in the USA: evaluating the role of the mode of administration. Psychol Med 2008; 38:1277.

30. L Dierker and E Donny. The role of psychiatric disorders in the relationship between cigarette smoking and DSM-IV nicotine dependence among young adults. Nicotine Tob Res 2008; 10:439.

31. M Miller et al. Cigarettes and suicide: a prospective study of 50,000 men. Am J Public Health 2000; 90:768.

32. N Breslau et al. Smoking and the risk of suicidal behavior: A prospective study of a community sample. Arch Gen Psychiatr 2005; 62:328.

33. CT Sweeney et al. Combination nicotine replacement therapy for smoking cessation: Rationale, efficacy and tolerability. CNS Drugs 2001; 15:453.

34. JR Hughes et al. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007; 1:CD000031.

35. LS Covey et al. Ameta-analysis of double-blind placebo-controlled trials of clonidine for smoking cessation. Br J Addict 1991; 86:991.

36. AV Prochazka et al. A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 1998; 158:2035.

37. CL da Costa et al. Stopping smoking: Aprospective, randomized, doubleblind study comparing nortriptyline to placebo. Chest 2002; 122:403.

38. AV Prochazka et al. A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation. Arch Intern Med 2004; 164:2229.

39. DK Hatsukami et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 2005; 78:456.

40. EJ Wagena et al. The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: Results of a randomized, placebo-controlled phase 1/2 trial. Nicotine Tob Res 2008; 10:213.

41. C Cohen et al. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: Reversal by the cannabinoid (cb1) receptor antagonist, rimonabant (sr141716). Neuropsychopharmacology 2005; 30:145.

42. ST Boyd and BA Fremming. Rimonabant - a selective CB1 antagonist. Ann Pharmacother 2005; 39:684.

43. BA Johnson et al. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: A randomized controlled trial. Arch Intern Med 2005; 165:1600.

44. RM Anthenelli et al. Preliminary evidence for gender-specific effects of topiramate as a potential aid to smoking cessation. Addiction (Abingdon, England) 2008; 103:687.

45. TP George et al. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry 2003; 53:136.

46. NR Anthonisen et al. The effects of a smoking cessation intervention on 14.5-year mortality: A randomized clinical trial. Ann Intern Med 2005; 142:233.

47. EJ Wagena et al. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med 2005; 165:2286.

48. SC Lazarus et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Amer J Respir Crit Care Med 2007; 175:783.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.